Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPO-3 tavapadon adjunct therapy trial in Parkinson's disease with motor fluctuations
MOH_2020-09-10_009291Phase 3Not yet recruiting
- Sponsor
- Cerevel Therapeutics
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Tavapadon add-on with Placebo add-on (2 arms). Primary endpoint: Change from baseline in total daily ON time without troublesome dyskinesia. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on MOH_2020-09-10_009291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-09-10_009291.